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Abstract
Background: Thymic carcinoma is a rare cancer with minimal evidence of a survival benefit following chemotherapy.
An oral fluoropyrimidine of S-1, however, is the recommended active cytotoxic chemotherapy agent for refractory
thymic carcinoma based on a case series, whereas sunitinib or everolimus are recommended as molecular-targeted
agents based on Phase II trials. We retrospectively investigated the efficacy of S-1 for refractory thymic carcinoma and
performed a biomarker analysis.
Methods: We assessed the clinicopathological variables of 14 consecutive patients who underwent S-1 for
refractory thymic carcinoma and correlated the clinical outcomes with potential biomarkers using
paraffin-embedded cancer tissues of eight patients in the cohort.
Results: A total of 178 thymic malignancies were identified, of whom 14 patients included 12 cases of squamous cell
carcinoma, one lymphoepithelioma-like carcinoma, and one undifferentiated carcinoma. Six patients exhibited a partial
response (42.9 %: 95 % confidence interval [CI], 21.4–67.4) and the disease control rate was 85.7 % (60.0–96.0 %). After a
median follow-up of 24.2 months, the median progression-free survival was 8.1 months (range, 2.6–12.2 months),
and median overall survival was 30.0 months (range, 6.2–41.9 months). No significant correlation between biomarker
expression and response was noted. However, thymidine synthase (TS)/dihydropyrimidine dehydrogenase and TS/
orotate phosphoribosyltransferase were observed.
Conclusions: S-1 for refractory thymic carcinoma offered clinical activity and achieved an 85 % disease control rate.
Although the biomarkers did not correlate with clinical outcome, the study results showed efficacy of S-1 as a cytotoxic
chemotherapy for refractory thymic carcinoma, which warrants future investigation.
Keywords: Thymic carcinoma, S-1, Rare cancer, Thymidine synthase, Orotate phosphoribosyltransferase,
Dihydropyrimidine dehydrogenase
Background
Rare cancers experience the crucial problem of slow in im-
provements of treatment and guideline because of the un-
feasibility of large clinical trials. Also, a concise pathological
diagnosis is often difficult. Recently, the RARECARE
project [1] supported by the European Commission, focus
on rare cancers to overcome these issues because they col-
lectively represent about 22 % of all cancer cases despite
the rarity of each of the individual 186 rare cancers [2].
According to the RARECARE definition, rare cancers
have an incidence of less than 6 per 100,000 persons per
year [3]. In addition, Rare Cancers Europe recently pub-
lished a consensus position paper for clinical trials in rare
cancers [4].
Thymic malignancies comprising of thymoma and
thymic carcinomas are rare cancers according to the
above definition. Thymic carcinoma represents a rare
and aggressive histological subtype of thymic epithelial
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tumors with the absence of thymic function, whereas
thymomas often have immunological complications. An
annual incidence of 0.15–0.32 per 100,000 person-years in
the United States and the Netherland is reported [5, 6].
Moreover, advanced stages at initial diagnosis are demon-
strated in thymic carcinoma with metastasis or extension
to surrounding tissues, whereas immune-active complica-
tions appears at early stages in thymoma. Thymomas can
be classified into five groups: A, AB, B1, B2, and B3.
Retrospective studies have shown types A and AB to have
better prognoses than B1, B2, B3, and carcinomas, with
thymic carcinoma in particular having a poor prognosis
compared with thymomas, with a 5-year survival rate of
30–50 %. [7–9] The Masaoka–Koga staging system is
widely accepted for both thymomas and thymic carcin-
omas, but this can lead to incorrect diagnoses, confusion
between clinical entities, and mixing of management strat-
egies. Treatment includes surgery for thymic carcinoma.
However, patients with metastatic thymic carcinoma are
treated with palliate-intent chemotherapy or best support-
ive care. Nevertheless, optimal chemotherapy has not
been determined because of the rarity. Platinum com-
bination chemotherapy with or without anthracycline is a
widely used chemotherapy for thymic carcinoma as first-
line chemotherapy, with response rates ranging from 20–
50 % [10, 11].
There is no known survival benefit to second-line
chemotherapy for refractory thymic carcinoma. According
to the National Comprehensive Cancer Network (NCCN)
guidelines for thymomas and thymic carcinomas, for pa-
tients with recurrent thymoma and thymic carcinoma, the
recommended chemotherapy is single-agent or clinical
trial [12]. Recent results of most molecular targeted agents
are disappointing; however, sunitinib [13] and erverolimus
[14] showed verified activities in a phase II study. Our
institution reported that cytotoxic chemotherapy is
anticipated for refractory thymic carcinoma based on
retrospective studies [15]. We have already reported the
clinical response of a small case series to S-1 in four
patients with refractory thymic carcinoma, which was
cited in the NCCN guidelines [16].
Many metabolic enzymes play key roles in the metabol-
ism of fluoropyrimidines, including S-1. Among these,
thymidine synthase (TS) is the rate-limiting enzyme in the
de novo synthesis of 2′-deoxy-thymidine-5′-monopho-
sphate, which is necessary for DNA synthesis and repair,
and is therefore the primary target of fluoropyrimidines
[17]. Dihydropyrimidine dehydrogenase (DPD) is the rate-
limiting enzyme in 5-fluorouracil (5-FU) catabolism [18],
while thymidine phosphorylase (TP) and orotate phos-
phoribosyltransferase (OPRT) convert 5-FU to active
metabolites such as 2′-deoxy-5-fluorouridine and 5-
fluorouridine-5′-monophosphate, respectively. Previous
studies found that increased expression levels of TS, DPD,
and TP, and reduced expression of OPRT in tumors, were
associated with low sensitivity to fluoropyrimidine-based
chemotherapy [17–20]. However, the correlation between
clinical outcome and the expression of these genes re-
mains unclear. Furthermore, thymic carcinomas show low
expression of TS, suggesting the potential therapeutic
value of TS-targeted agents including fluoropyrimidine or
antifolate agents [21]. However, no studies have focused
on chemotherapy in relation to TS expression in thymic
carcinomas.
In this investigation, we retrospectively evaluated the
clinical outcomes of S-1 treatment in 14 consecutive pa-
tients with refractory thymic carcinoma with progressive
disease after at least one prior session of platinum-based
chemotherapy. We also analyzed the mRNA expression
levels of TS, DPD, OPRT, and TP to identify potential
biomarkers of S-1 response.
Methods
Database for clinical data and acquisition of cancer
specimens
Among total of 178 thymic malignancies (100 thymoma
and 78 thymic carcinoma) were identified, a series of 13
patients with thymic carcinoma was treated at Tokyo
Metropolitan Cancer and Infectious diseases Center
Komagome Hospital (Tokyo, Japan) among April 1987
and December 31, 2014. Also, one patient at Japan Red
Cross Medical Center (Tokyo Japan), for a total of 14
consecutive patients. All patients had histologically con-
firmed metastatic or relapsed thymic carcinoma not
amenable to curative-intent treatment and disease pro-
gression after failure of at least one previous treatment
with platinum-based chemotherapy. The diagnosis was
confirmed with immunohistochemistry using CD5 and/or
c-Kit to exclude other thoracic malignancies, and terminal
deoxynucleotidyl transferase (TdT) to distinguish from
thymoma. We evaluated laboratory data from all patients,
and targeted lesion responses were determined with com-
puted tomography. All patients who were treated with
chemotherapy gave informed consent.
In the present analysis, we collected and assessed
treatment outcomes according to the International
Thymic Malignancies Interest Group (ITMIG) Policies
and Management [22]. The medical records and labora-
tory data of each patient were retrieved for analysis and
assessment according to treatments for thymic carcinoma,
and associated complications were also reviewed. Data on
significant hematological and non-hematological toxicities
associated with chemotherapy were also collected.
The baseline demographic characteristics are sum-
marized in Table 1. The median age of all patients
was 56 years (range, 14 to 81 years). On histology,
there were three subtypes of thymic carcinoma: squamous
cell carcinoma (SQC), undifferentiated carcinoma, and
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lymphoepithelioma-like carcinoma. No cases of myasthe-
nia gravis or other associated symptomatic paraneoplastic
syndromes were observed.
Treatment with S-1
All patients had been previously treated with
fluoropyrimidine-agent besides those previously treated
with platinum-based chemotherapy as a front-line ap-
proach. Also, all of the 14 patients that were adminis-
trated S-1 had an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of less than 2 with
reserve adequate bone marrow. Also, physicians were
complied with the assurances of safety provided to the
Taiho Pharmaceutical Co. to promise safety. The initial
dose of S-1 was determined based on body surface area
(BSA): 80 mg daily for BSA <1.25 m2; 100 mg daily for
1.25 < BSA <1.5 m2; and 120 mg daily for BSA ≥1.5 m2.
The drug was taken twice daily for 4 weeks, followed by
2 weeks-off, which comprised a cycle. In cases of poor
PS, mild organ impairment, elderly patients, or other
reasons suggesting intolerability, the dose was decreased
stepwise or given for 2 weeks-on and followed by a
1-week drug-free interval per cycle. If a dose reduc-
tion of 20 % was required, the patients continued to
receive the reduced dose throughout their treatment.
Assessment and outcomes
The benefits of treatment were retrospectively evaluated
using the following: response rate, disease control rate,
progression-free survival (PFS), overall survival (OS),
and 1-year survival rate. We assessed treatment efficacy
of S-1 using the Response Evaluation Criteria in Solid
Tumors criteria version 1.1 (RECIST). Patients were
assessed at least every 2 months by CT. S-1 treatment
was reported from the date of the first cycle to confirm
of disease progression. Disease control rate was defined
as objective responder plus stable disease. PFS was
calculated from the first date of S-1 until the date of
confirmed progression, early discontinuation of treat-
ment, or death from any cause and was censored at the
date of the last follow-up visit for patients who were still
alive and who had not progressed. OS was defined as the
interval between the first date of treatment to the time of
death from any cause or the last follow-up evaluation.
Patients who were alive on the date of last follow-up were
censored on that date. Because of the retrospective nature
of the data, these relevant end points were chosen to re-
flect clinical practice.
Hematological and non-hematological toxicities related
to chemotherapy were described using the common
toxicity criteria according to the Common Terminology
Criteria for Adverse Events version 4.0 (CTCAE v4.0)
from medical records.
Tumor quantitative assessment for reverse
transcription-PCR
In the available cohort, eight specimens that were
treated with S-1 and capecitabine, a similar fluoropyri-
midine agent, were evaluated for potential biomarkers
with formalin-fixed paraffin-embedded (FFPE) primary
thymic carcinoma specimens (5 core needle biopsy, 2
surgical specimens, and 1 excision biopsy) at diagnosis
using PCR quantification of mRNA expression of TS,
DPD, OPRT, and TP. In the other five patients, sufficient
specimens were not obtained for analysis because of
core-needle biopsies or decalcified processes with bone
metastasis.
Representative hematoxylin and eosin-stained slides
from FFPE specimens were reviewed by a pathologist for
a manual macrodissection of tumor tissue. Tumor tissue
was selected and dissected using a scalpel. RNA was
Table 1 Demographic and baseline patient characteristics
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isolated from tumor tissue using RNeasy FFPE Kit
(Qiagen, Chatsworth, GA, USA). cDNA was prepared
using High Capacity Reverse Transcription Kit (Life
Technologies, Foster City, CA, USA) according to the
manufacturer’s instructions.
The expression levels of four genes were determined
using TaqMan real-time PCR (TaqMan array card; Life
Technologies) after TaqMan assay-based pre-amplification.
Briefly, cDNA (2.5 μL) was pre-amplified using TaqMan
PreAmp Master Mix (2×; Life Technologies) and a pool of
TaqMan® Gene Expression Assays (0.2×) in a 10-μL PCR
reaction. The pre-amplification cycling conditions were as
follows: 95 °C for 10 min followed by 14 cycles of 95 °C
for 15 s and 60 °C for 4 min. An amplified cDNA sample
was diluted 20 times in TE Buffer. Next, 25 uL of ampli-
fied cDNA was added to 25 μL of RNase-free water and
50 μL of 2× TaqMan Gene Expression Master Mix (Life
Technologies). The mixture was then transferred into a
loading port for the TaqMan array card. The card was
centrifuged twice, sealed, and PCR amplification was
performed using the Applied Biosystems Prism 7900HT
Sequence Detection System (Life Technologies) under the
following thermal cycling conditions: 50 °C for 2 min and
94.5 °C for 10 min followed by 40 cycles of 97 °C for 30 s
and 59.7 °C for 1 min. The array card included ACTB,
GAPDH, and RPLP0 as references based on their proven
roles as housekeeping genes [23, 24]. The assay IDs used
in the array card are shown in Additional file 1: Table S1.
The cycle threshold (Ct) value, which is inversely propor-
tional to the amount of cDNA, was calculated. The gene-
expression (relative mRNA) levels were expressed as
the ratio (the differences between the Ct values) be-
tween the gene of interest and the geometric mean of
the reference genes, which provided a baseline meas-
urement for the amount of mRNA isolated from a
specimen.
Statistical methods
PFS and OS were estimated according to the Kaplan–
Meier method. Differences between tumor response of
S-1 and the mRNA expression of TS, TP, DPD, or OPRT
were evaluated with the Wilcoxon rank sum test. We
also analyzed four biomarkers and responders with a
correlation coefficient matrix. All statistical analyses
were carried out using JMP 11 (SAS Institute Inc., Cary,
NC, USA). A P-value less than 0.05 was considered sig-
nificant. This retrospective study was approved by the
institutional review board (IRB) of Tokyo Metropolitan
Cancer and Infectious diseases Center Komagome
Hospital (#1049). Written informed consent was ob-
tained from each patient before use of S-1 for advanced
thymic carcinoma in the clinical setting, however, the
IRB waived the requirement for obtaining informed con-
sent to biomarker analysis with tumor specimens.
Results
Treatment efficacy
Disease control was observed in 12 patients (85.7 %),
with 6 partial responses (42.9 %) recorded. There were
no complete responders (Fig. 1a). The median PFS
was 8.1 months (95 % confidence interval [CI], 2.6–
12.2 months), while the median OS was 30.0 months
(95 % CI, 6.2–41.9 months) after a median follow-up
of 24.2 months. PFS and OS curves are shown in
Fig. 1b, and effectiveness is summarized in Table 2.
The 1-year survival rates were 68.8 %. Previous lines
of chemotherapy included an average of two lines.
Grade 3 and 4 treatment related toxicities in CTCAE
was seen in 21.4 % of patients. Among them, six patients
needed a dose reduction because of toxicities and treat-
ment was discontinued in four patients before progres-
sion. In these patients, treatment was stopped early to
preserve the benefits achieved. Two patients requested
that treatment be stopped due to anorexia. There were
no toxic deaths.
TS, DPD, OPRT, and TP mRNA expression
Histograms of the expression values for each gene are
shown in Fig. 2a. Each relative mRNA level at their re-
spective 95 % CIs was as follows: TS relative mRNA ex-
pression levels had median values of 7.81 (2.44–14.30),
DPD 3.56 (2.14–7.49), OPRT 2.24 (1.06–12.04), and TP
3.36 (0.22–7.48). A correlation between the expression
of TS, DPD, TP, and OPRT genes on survival in this co-
hort was not seen. There was a significant association
between TS and DPD or TS and OPRT mRNA expres-
sions in each group (Fig. 2b).
Discussion
The present retrospective study demonstrated the poten-
tial activity of S-1 in 14 patients with refractory thymic
carcinoma. However, a significant correlation between
S-1 response and hypothesized biomarkers was not seen.
Platinum-combination chemotherapy plays an import-
ant role in the first-line chemotherapy for advanced
thymoma and thymic carcinoma [11]. However, the
rarity of this disease has hampered the development of
an optimal chemotherapy regimen. The clinical benefit
of chemotherapy remains uncertain compared with the
best supportive care for thymoma and thymic malignan-
cies. For refractory thymoma and thymic carcinoma, the
NCCN guidelines [12] recommend single-agent or non-
platinum-based chemotherapy, such as etoposide [25],
gemcitabine [26], paclitaxel [27], ifosfamide [28], peme-
trexed [29], 5-fluorouracil (5-FU) and leucovorin [30],
and octreotide (including long acting-formulation) plus
prednisolone [31]. The NCCN guidelines do not provide
separate recommendations for thymic carcinoma and
thymoma [32]. Amrubicin [33], docetaxel [34], and S-1
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[16, 35, 36] were reported to be effective for thymic car-
cinoma. Recently, molecular investigations and clinical
outcomes of thymic malignancies have demonstrated
that thymoma and thymic carcinoma are separate
diseases and classified according to the World Health
Organization 2004 [37]. Therefore, the ITMIG recom-
mends further investigation to differentiate these cancers
as two separate categories and to not combine them as
was the case in the past. A European collaborative inves-
tigation also demonstrated that the prognosis for thymic
carcinoma in children was poor compared with that for
thymoma [38]. Molecular targeted agents are currently
being investigated. Based on c-Kit gene mutant status,
drugs that inhibit c-Kit, such as imatinib [39], sorafenib
[40], and sunitinib [41], may provide better results [42].
Recent trials with molecular targeted drugs did not meet
expectations (Table 3). However, sunitinib, and everoli-
mus for refractory thymic carcinoma, and cixutumumab
for refractory thymoma have an anticipated clinical
benefit in phase II studies. If limited to case series, cyto-
toxic chemotherapy demonstrates clinical activity for
refractory thymic carcinoma [15]. The endpoints of
time-to-event have influence on the selection bias easier
than response rate except for the efficacy of chemo-
therapy, such as the progress of supportive care, there-
fore, suggesting that response rate is a suitable endpoint
for comparing chemotherapeutic regimens.
S-1 (TS-1; Taiho Pharmaceutical Co., Ltd, Tokyo, Japan)
is an oral fluoropyrimidine agent composed of tegafur,
5-chrolo-2, 4-dihydroxypyridine (gimeracil: CDHP), and
a
b
Fig. 1 Clinical outcome of S-1 for relapsed thymic carcinoma. a Best response of targeted lesions to S-1 treatment. b (i) and (ii) Kaplan–Meier
analyses for PFS and OS of S-1 in refractory thymic carcinoma
Table 2 Clinical outcome of S-1 treatment for refractory thymic
carcinoma
Clinical outcome N° of patients (n = 14)
Response to chemotherapy N (%) 95 % CI
Complete response 0 (0 %)
Partial response 6 (42.9 %) [21.4–67.4]
Stable disease 6 (42.9 %) [21.4–67.4]
Progression disease 2 (14.3 %) [0.04–39.9]
Median response duration, moths [95 % CI] 8.1 [2.6–12.2]
Median overall survival, months [95 % CI] 30.0 [6.2–41.9]
1-year survival rate, % 68.8
CI confidence interval
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oteracil potassium (oxonic acid: Oxo) in a molar ratio of
1:0.4:1. TS, a critical source of thymidine nucleotides for
DNA synthesis and repair, is the target enzyme for
5-FU metabolite and 5-fluoro-deoxyuridinemonophosphate
(FdUMP). Several studies have demonstrated that high
expression of TS level correlates with 5-FU resistance in
various cancers. 5-FU is then degraded by DPD, which
inhibits TS. CDHP competitively inhibits DPD, which is
involved in the degradation of 5-FU, thereby increasing
serum 5-FU concentrations. It is expected to act more
intensively than older fluoropyrimidine agents, but in-
creased 5-FU concentrations in the intestinal mucosa
leads to severe gastrointestinal toxicities. Oxo inhibits
diarrhea by selective inhibition of OPRT and palliates diar-
rhea. Therefore, intensive treatment with S-1 is available
with Oxo to reduce GI toxicity. Currently, S-1 has demon-
strated activity against a broad spectrum of solid tumors,
such as gastric cancer, head and neck cancer, non-small
cell lung cancer, pancreatic cancer, bile duct cancer, breast
cancer, and colon cancer.
The response rate of the present study was 42.9 % with
a 95 % CI of 21.4–67.4 and a median progression-free
survival of 8.1 months (2.6–12.2). Sunitinib is a promis-
ing agent with the biological plausibility of inhibition for
c-Kit and antiangiogenic effects [41]. Everolimus was
tested for thymic malignancies in a phase I study [14]
and inhibition of a common cancer signaling pathway,
serine–threonine kinase mammalian target of rapamycin
(mTOR), is proposed. However, our results did not pro-
vide the promising biological plausibility of S-1 for
a
b
Fig. 2 Correlation to expression of TP, DPD, OPRT, and TP in tumour specimens (a) Relationship between biomarkers and tumour response. (i) DPD,
(ii) TP, (iii) TS, and (iv) OPRT. b Correlation between biomarkers. b (i) DPD, TP, TS, and OPRT; (ii) correlation between responders and non-responders
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thymic carcinoma. On the other hand, the cost-benefit is
also different among these agents and is of interest. Calcu-
lating from the results of median PFS from phase II trials
of sunitinib, everolimus, and the present retrospective
study of S-1 for thymic carcinoma, a total of 7.2 months
of sunitinib treatment costs about 30,000 EUR (5,700 EUR
per each cycle (6 weeks)), and a total of 12.1 months of
everolimus treatment costs 68,500 EUR (7,300 EUR per
6 weeks), and a total of 8.1 months of S-1 treatment
costs 4,200 EUR (700 EUR per cycle (6 weeks)). With a
cost–benefit balance, cytotoxic agents should progress in
clinical trials or observational studies because response
rates even in second-, third-, and fourth-lines of cytotoxic
chemotherapy in our result decreased to 39.1 %, 23.1 %,
and 12.5 %, respectively [15]. As for suggested biomarkers
for S-1, thymic carcinoma showed significantly progres-
sively decreased levels of TS mRNA expression from type
B1 to carcinoma. Kaira et al. demonstrated that TS was
potentially correlated with TS in thymic carcinoma using
immunohistochemistry staining [43]. Therefore, the pos-
sible biological plausibility for S-1 activity in thymic car-
cinoma was suggested. However, the present study did not
show a significant relationship between response and ex-
pression of biomarkers. However, a correlation between
TS/DPD and TS/OPRT may potentially be seen in the
Fig. 2. Unfortunately, the results are inconclusive because
of small sample size and the number of specimens ana-
lyzed at diagnosis. TS, OPRT, and DPD are definitive
biomarkers for fluoropyrimidine is not always active with
a biological plausibility in thymic carcinoma. Also, TP was
not unclear to anticipate to be active of capecitabine.
The key limitation of the present study was the small
number of patients and the lack of accurate clinical con-
firmation of response and time-to-events because of its
retrospective nature. However, this is a common limita-
tion of retrospective studies of rare cancers. Second, the
methodology of analysis for TS, TP, OPRT, and DPD
mRNA expression were examined in the small number
of specimens at initial diagnosis. Thus, histological fea-
tures or characteristics might have been modified by
prior chemotherapy. The main reason for the unavaila-
bility of specimens for biomarker analysis was scant tissue
from core needle biopsy for advanced stage, whereas suffi-
cient specimen volumes were obtained for recurrent cases.
This results of the present study support the multicen-
ter, uncontrolled, open-label phase II trial to confirm
our findings at three cancer centers in Tokyo (National
Cancer Center Hospital, The Cancer Institute Hospital
of the Japanese Foundation for Cancer Research, and
Tokyo Metropolitan Cancer and Infectious diseases
Center Komagome Hospital) that were launched
(UMIN000010736) with a central pathological diagnosis
and referring to the position paper in rare cancer trial
[4]. However, clinical evidence for rare cancers is chal-
lenging and hampers enrolling patients. The enriched
expression of PD-L1 in thymic carcinoma cancer cells
Table 3 Chemotherapy and molecular-targeted agents for refractory thymic carcinoma
Authors Agent Study design Target Number Response rate (DCR) PFS (month) OS (month)
Cytotoxic agents
Loehrer et al. [29] Pemetrexed Ph II - 11 NR 1.3 N/A
Wakelee et al. [33] Amrubicin Ph II - 19 10.5 % 8.5 18.1
Liang et al. [46] Pemetrexed Retrosp - 10 10.0 % 6.5 12.7
Palmieri et al. [47] Capecitabine + gemcitabine Ph II - 8 37.5 % 6 (3–10) N/A
The present study S-1 Retrosp - 14 42.9 % 8.1 30.0
Molecular targeted agents
Thomas et al. [13] Sunitinib Ph II c-KIT, PDGFR 23 26 % (65 %) 7.2 Not reached
Zucali et al. [14] Everolimus Ph II mTOR 12 25 % (41 %) 12.1a 24.0a
Rajan et al. [48] Cixutumumab Ph II IGF-1R 12 0 % 1.7 8.4
Giaccone et al. [49] Belinostat Ph II HDAC 16 0 % (50 %) 5.8 12.4
Besse et al. [50] Milciclib (PHA-848125 AC) Ph II CDK, src family 26 - - -
Bedano et al. [51] Erlotinib + bevacizumab Ph II EGFR, VEGF 7 0 N/A N/A
Kurup et al. [52] Gefitinib Ph II EGFR 7 0 N/A N/A
Giaccone et al. [53] Imatinib Ph II c-KIT mutation 5 0 N/A N/A
Loehrer et al. [54] Octreotide + prednisone Ph II somatostatin receptor 6 0 4.5 23.4
Gubens et al. [55] Saracatinib (AZD0530) Ph II src family 9 0 3.6 6.7
n number, PFS progression-free survival, DCR disease control rate, OS overall survival, Ph II phase II, Retrosp retrospective, IGF-1R insulin-like growth factor 1 receptor,
HDAC histone deacetylase, PDGFR platelet-derived growth factor, CDK cyclin-dependent kinase, mTOR mammalian target of rapamycin. EGFR epidermal growth factor,
VEGF vascular endothelial growth factor
aSurvival data include thymoma and thymic carcinoma
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suggests that immune-checkpoint inhibitors may repre-
sent an interesting new therapeutic modality for thymic
carcinomas (NCT02364076) [44, 45]. However, suitable
biomarkers for immune-checkpoint inhibitors remain un-
certain, and cytotoxic chemotherapy for relapsed thymic
carcinoma should thus be developed simultaneously.
Conclusions
The present retrospective analysis of 14 patients with re-
fractory thymic carcinoma who were treated with single
agent S-1 demonstrated clinical activity. Further clinical
management strategies and treatments for refractory
thymic carcinoma should be investigated.
Additional file
Additional file 1: Table S1. Clinical characteristics of patients treated
with S-1 for refractory thymic carcinoma. (DOCX 18 kb)
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